Crossmark

Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening

Crossref DOI link: https://doi.org/10.1186/s12985-019-1216-7

Published Online: 2019-08-22

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gustavsson, Inger

Aarnio, Riina

Myrnäs, Mattias

Hedlund-Lindberg, Julia

Taku, Ongeziwe

Meiring, Tracy

Wikström, Ingrid

Enroth, Stefan

Williamson, Anna-Lise

Olovsson, Matts

Gyllensten, Ulf https://orcid.org/0000-0002-6316-3355
Funding

Funding for this research was provided by:

Swedish Cancer Foundation (X)

ALF grants (x)

South African Medical Research Council (X)

FORTE - Swedish Research Council (X)
License Information

Text and Data Mining valid from 2019-08-22

Version of Record valid from 2019-08-22
More Information

Article History

Received: 19 June 2019

Accepted: 14 August 2019

First Online: 22 August 2019

Ethics approval and consent to participate

: Informed consent was obtained from all study participants. Ethical approval number 2017/088.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below